



ARAŞTIRMA/RESEARCH

The analysis of the phenylalanine hydroxylase gene mutations by sequencing and ARMS techniques in Turkish patients

Türk hastalarda fenilalanin hidroksilaz gen mutasyonlarının dizileme ve ARMS teknikleri ile incelenmesi

Ümit Lüleyp¹, Perçin Pazarcı¹, Gamze Cömertpay¹, Halise Neslihan Önenli², Ayfer Pazarbaşı¹, Davut Alptekin¹, Halil Kasap¹, Ursula Froster³

¹Cukurova University, Faculty of Medicine, Department of Medical Biology and Genetics, ²Department of Pediatric Metabolism and Endocrinology, Adana, Turkey

³ University of Leipzig Faculty of Medicine, Institute of Human Genetics, Leipzig, Germany

Cukurova Medical Journal 2016;41(4):702-708.

Abstract

Purpose: Phenylketonuria is an autosomal recessive deficiency of the hepatic enzyme phenylalanine hydroxylase. With this study, detection of the most frequent phenylalanine hydroxylase gene mutations in Turkish population is aimed.

Material and Methods: 23 unrelated phenylketonuria patients (46 alleles) who are living in Cukurova region, Turkey were investigated. First, all exons were screened by using DHPLC method then the direct sequencing technique and ARMS methods were used to analyze mutation suspected samples.

Results: IVS10-11g→a splicing mutation in 27 alleles (58.7%), R261Q mutation in 7 alleles (15.2%) and E178G, P281L, R243X, R243Q, R408W, Y386C mutations, all in a frequency of 2/46 (4.3%) is found.

Conclusion: The arginine amino acid, accounting for 68.4% of changes in exon sites 7 and 12, where R243X, R243Q, R261Q and R408W mutations occur, is thought to be important for amino acid changes in phenylalanine hydroxylase gene among phenylketonuria patients in Çukurova region. Single-base mutations like IVS10-11g→a and P281L could be detected with an accuracy of 100% by the use of specifically designed primers by authors according to ARMS technique and it is relatively cheaper and requesting less technical equipment.

Key words: ARMS, DHPLC, Phenylketonuria, sequencing, Turkish population

Öz

Amaç: Fenilketonüri, hepatik bir enzim olan fenilalanin hidroksilazın otozomal resesif bozukluğu sonucu ortaya çıkan bir durumdur. Bu çalışmada, Türk popülasyonunda en sık görülen fenilalanin hidroksilaz geni mutasyonlarını belirlemek amaçlandı.

Gereç ve Yöntem: Öncelikle tüm ekson bölgeleri DHPLC metodu kullanılarak tarandı. Ardından mutasyon şüphesi taşıyan örnekler sekanslama ve ARMS yöntemleri kullanılarak analiz edildi.

Bulgular: IVS10-11g→a splayzing mutasyonu 27 allelde (%58,7), R261Q mutasyonu 7 allelde (%15,2) ve E178G, P281L, R243X, R243Q, R408W, Y386C mutasyonları ise 2'şer allelde (%4,3) tespit edildi.

Sonuç: R243X, R243Q, R261Q ve R408W mutasyonlarının oluştuğu 7 ve 12'inci ekson bölgelerinde arginin aminoasidinin değişimi Çukurova bölgesindeki fenilketonüri hastalarında fenilalanin hidroksilaz geni mutasyonlarında önemli bir yer tutmaktadır (%68,4). IVS10-11g→a ve P281L gibi tek baz mutasyonları bizim tarafımızdan dizayn edilmiş primerler ve ARMS tekniği kullanılarak daha ucuza, daha az teknik ekipmanla ve %100 doğrulukla tespit edilebilmektedir.

Anahtar kelimeler: ARMS, DHPLC, Fenilketonüri, dizileme, Türk popülasyonu

Yazışma Adresi/Address for Correspondence: Dr. Ümit Lüleyp, Cukurova University, Faculty of Medicine, Department of Medical Biology and Genetics, Adana, Turkey. E-mail: umitluleyp01@gmail.com
Geliş tarihi/Received: 02.05.2016 Kabul tarihi/Accepted: 07.06.2016

INTRODUCTION

Phenylketonuria (PKU) is caused by the deficiency of the phenylalanine hydroxylase enzyme (PAH) and is an autosomal recessive disorder. Unless the intake of phenylalanine is restricted, it results in severe hyper-phenylalaninaemia and mental retardation¹. More than 950 different mutations in PAH gene have been defined up to date (PAHdb; <http://www.pahdb.mcgill.ca/>) since the identification of the PAH gene in 1986².

Classical methods such as SSCP (Single Strand Conformational Polymorphism) and DGGE (Denaturing Gradient Gel Electrophoresis) are used for screening of mutations in genes that consist many exons³. Recently, DHPLC (Denaturing High-Performance Liquid Chromatography Technique) has been the preferred method for the analysis of genes such as; BRCA1⁴, BRCA2⁵ and CFTR⁶ because of its advantages in comparison to these classical methods. The same is valid for screening the mutations of the PAH gene. The detection of mutations is possible by different molecular techniques like ARMS (Amplified Refractory Mutation System), ASO (Allele Specific Oligonucleotide), RFLP (Restriction Fragment Length Polymorphism) and sequencing where preference is made according to the type of mutation, the study target, the sensitivity and specificity of the methods used and the capability of each laboratory. We aimed to detect the most frequent PAH gene mutations in Turkish population, firstly for-screening the mutated exons by DHPLC then determining the exact nature of mutations by ARMS technique, which is relatively cheaper and not requesting a large technical capability.

MATERIALS AND METHODS

The DNA samples were collected from 23 unrelated patients (46 independent alleles), that are living in Çukurova Region, Adana /Turkey, with classical PKU, diagnosed on the basis of the initial plasma phenylalanine (PA) concentrations and positive urine ferric chloride test in the University of Çukurova, Faculty of Medicine, Department of Pediatric Endocrinology and Metabolic Diseases (Adana/Turkey), and the samples transported to Germany and stored at the Institute of Human Genetics in Leipzig.

Study is approved by the human studies ethical committee of the Cukurova University.

PCR amplification

Blood samples were preserved in EDTA and Genomic DNA was extracted from samples by using standard procedures⁷. 50 µl reaction volumes containing approximately 200 ng DNA in KCL (10mM), 50 µmol of each primer, Tris-HCL (1.5 mM), MgCl₂ (200 µM) of each dNTP and IU TaqGold-Polymerase (PE) were used for amplification of samples. For PCR reaction, denaturation was done at 95°C for 10 min, 30 cycles of 1 min. at 95°C, 1 min at the fragment-specific annealing temperature and 1 min at 72°C. After 30 cycles another extension step of 10 min at 72°C was done.

Primers were designed to obtain fragments between 150 and 300 bp by using the Gene-Runner software (www.generunner.net). Table 1 shows the primers, length of PCR products and the annealing temperatures for each of the PAH exons and also the primers used for ARMS method for IVS10-11g→a and P281L. Additionally; three primers were designed as “normal”, “mutant” and “common” to determine the allele status of each specific mutation to detect single base substitution i.e. IVS10-11g→a and P281L mutations by ARMS technique. Normal primers were designed with a change pertaining only to previous nucleotide in 3' end (C highlighted in Table 2) and this substitution detects with the aim of detecting the normal alleles.

In the detection of mutant alleles, changes comprised the last two nucleotide in 3' end (C and A highlighted in Table 2) corresponding to the mutation point of the mutant primers, considering the g→a (IVS10-11g→a) and C→T (P281L) base substitutions with necessary changes to increase the specificity of the amplification of the last nucleotide⁸ (Table 1). Primers were designed using Gene Runner program. DHPLC analysis was done by using an automated DHPLC device (WAVE: Transgenomic, San Jose, CA, USP) according to manufacturer's manual. PCR products (5-15 µl and 10-100 ng DNA each) were denaturized at 95°C for 5 min and re-annealed gradually by decreasing the sample temperature from 95 to 65°C over a period of 30 min³.

Sequence analysis

Abnormal DHPLC patterns were noted and these samples were examined to identify sequence variants by using automated sequence analysis on ABI Prism 377 (Applied). Afterwards, sequence variants were classified according to international databases

(<http://www.pahdb.mcgill.ca/>) by using the re-amplified PCR products of these fragments.

Statistical analysis

Descriptive analysis is used to evaluate the results.

Table 1. The list of the primers of PAH gene used in sequencing and ARMS techniques

| Type of Technique | Primer No | Sequence 5' → 3' | Product Length (bp) | Annealing Temperature |
|----------------------|------------------------|--------------------------|---------------------|-----------------------|
| DHPLC and Sequencing | PAH For Ex2 | TTCATGCTTGCTTTGTCC | 299 | 50 |
| | PAH Rev Ex2 | CTGTTCCAGATCCTGTGTTC | | |
| | PAH For Ex3 | TGTGACTGTCTCCTCACC | 265 | 50 |
| | PAH Rev Ex3 | GACATGTGAGTTACTTATGTTG | | |
| | PAH For Ex4 | TGTACTCAGGACGTTGCCTTC | 146 | 54 |
| | PAH Rev Ex4 | CTCATCTACGGGCCATGGAC | | |
| | PAH For Ex5 | AAGCATTTCATAAAGGTACCAG | 202 | 52 |
| | PAH Rev Ex5 | AAGGGAGAAGCAGGCTAG | | |
| | PAH For Ex6 | TAACCTGCATTTCTGCTGTG | 317 | 53 |
| | PAH Rev Ex6 | TCCTCTGCCTCAATCCTC | | |
| | PAH For Ex7 | TGCCTCTGACTGAGTGGTG | 242 | 55 |
| PAH Rev Ex7 | AAGATGGCGCTCATTGTG | | | |
| DHPLC and Sequencing | PAH For Ex8 | CTGCCCATTCTCATGTAGA | 226 | 56 |
| | PAH Rev Ex8 | CTGGGCTCAACTCATTGAG | | |
| | PAH For Ex9 | ATGGCCAAGTACTAGGTTG | 199 | 54 |
| | PAH Rev Ex9 | AGTTTCAAAGACCTGAGGGC | | |
| | PAH For Ex10 | TCCCAGTCAAGGTGACAC | 260 | 50 |
| | PAH Rev Ex10 | GGATACAAATAGGGTTTCAAC | | |
| | PAH For Ex11 | TGCAGCAGGGAATACTGATC | 293 | 56 |
| | PAH Rev Ex11 | TAGACATTGGAGTCCACTCTC | | |
| | PAH For Ex12 | ATGCCACTGAGAACTCTCTT | 245 | 50 |
| | PAH Rev Ex12 | AGTCTTCGATTACTGAGAAA | | |
| | PAH For Ex13 | TCACTAGGACACTTGAAGAG | 163 | 48 |
| PAH Rev Ex13 | TCTCCATCAACAGATTCAC | | | |
| ARMS | IVS10-11g→a Normal For | AGTGATAATAACTTTTCACTCG | 265 | 60 |
| | IVS10-11g→a Mutant For | ACAGTGATAATAACTTTTCACTCA | | |
| | IVS10-11g→a Common Rev | ATAGACATTGGAGTCCACTCTC | | |
| ARMS | P281L Normal Rev | GCTGGAGGACAGTACTCATG | 211 | 60 |
| | P281L Mutant Rev | GCTGGAGGACAGTACTCATA | | |
| | P281L Common For | GTGCCTCTGACTGAGTGGTG | | |

Table 2. The ARMS primers designed for the detection of IVS mutation

| Primer (5' → 3') | Function |
|--|-----------------------|
| CAGTGATAATAACTTTTCACCTTG | DNA Sequence |
| CAGTGATAATAACTTTTCACCTC ¹ G | Normal Forward primer |
| ACAGTGATAATAACTTTTCACCTC ¹ A ² | Mutant Forward primer |
| ¹ Nucleotide substitution in normal and mutant primers | |
| ² Nucleotide substitution in mutant primer specific to the g→a mutation | |

Table 3. The distribution of mutations and polymorphisms in PAH gene detected by DHPLC and sequencing analysis techniques

| Gene : PAH | Amino acid change | Nucleotide change | Nucleotide position (cDNA) |
|--------------|-------------------|-------------------|----------------------------|
| Exon 6 | E178G | GAA/GGA | 533A>G |
| Exon 7 | R243X | CGA/TGA | 727C>T |
| | R243Q | CGA/CAA | 728 G>A |
| | R261Q | CGA/CAA | 728G>A |
| | P281L | CCG/CTG | 842V>T |
| Intron 10 | IVS10-11g→a | 1066-11g→a | 1066-11g→a |
| Exon 11 | Y386C | TAT/TGT | 1157>G |
| Exon 12 | R408W | CGG/TGG | 1222 C>T |
| Polymorphism | Q232Q | - | - |
| | V245V | - | - |

Table 4. Allelic distribution of PAH gene mutation and its frequency

| Number of Patient | Polymorphism | Allele 1 | Allele 2 | % | Frequency |
|-------------------|--------------|----------|----------|------|-----------|
| 10 | 1 V245V | IVS10 | IVS10 | 58.7 | (27/46) |
| 3 | | IVS10 | R261Q | 15.2 | (7/46) |
| 2 | | IVS10 | P281L | 4.3 | (2/46) |
| 2 | | IVS10 | E178G | 4.3 | (2/46) |
| 1 | 1 V245V | R243X | R243X | 4.3 | (2/46) |
| 1 | | R243Q | R243Q | 4.3 | (2/46) |
| 2 | 1 V245V | R261Q | R261Q | 4.3 | (2/46) |
| 1 | | Y386C | Y386C | 4.3 | (2/46) |
| 1 | | R408W | R408W | 4.3 | (2/46) |
| | | | | 7 | |
| Total 23 patients | | | | | |

RESULTS

Mutations and polymorphisms that are found by sequencing the mutation suspected samples determined by DHPLC analysis are shown in Table 3. The IVS10-11g→a splicing mutation was observed in 17 patients, 10 of them have homozygous form and 7 of them have heterozygous form, with a total of 27 (58.7%) of 46 alleles (Table 3, Table 4). The R261Q mutation was the second most frequent mutation observed in 5 patients, 2 of them have homozygous form and 3 of them have heterozygous form with IVS mutation, with a total

of 7 (15.2%) alleles out of 46. Both P281L and E178G mutations were seen in 2 patients respectively in a heterozygous form combined with IVS mutation and the frequency was 4.3% (2/46), while R243X, R408W, Y386C and R243Q mutations were seen in homozygous form each in one patient with a frequency of 4.3% (2/46) (Table 3, Table 4).

Samples, determined to possess homozygous or heterozygous IVS mutation by sequencing analysis, were re-analyzed by ARMS technique using newly designed primers. The results were 100% in accordance with the results of the sequencing

analysis, without any non-specific bands; hence they indicated that ARMS technique could be used with sufficient accuracy (Figure 1-a and Figure 2-a). The detection of one patient with P281L mutation presented in heterozygous form revealed the ability

of newly designed ARMS primers to detect the related mutation with the same accuracy of sequencing analysis technique (Figure 1-b and Figure 2-b).




Figure 1. a-b. Gel slides of IVS10-11g→a and P281L mutations detected by ARMS. IVS10-11g→a mutation (a). P281L mutation (b). (Mw marker: pUC18/19 Msp I, Line 1=Negative control, Lines 2, 3= Homozygous Normal allele, Lines 4, 5=Heterozygous allele, Lines 6, 7=Homozygous mutant allele (N=Normal, M=Mutant), Internal controls: TNF α primers; RDN-010-025)




Figure 2. a-b. Electropherograms of IVS10-11g→a and P281L mutations detected by sequencing. IVS10-11g→a mutation (a). P281L mutation (b).

DISCUSSION

Since PAH deficiency is an inherited disorder seen in Caucasians frequently, the population genetics of disease has taken a lot of interest from researchers. Extensive mutation data have been published for most countries as a result of researches over the last

decade. Spectrum of mutations and the degree of heterogeneity differ distinctly between regions⁹.

In a recent review, Blau¹⁰ states that “Most PAH patients have compound heterozygous PAH gene variants and one mutated allele may markedly influence the activity of the second mutated allele, which in turn may influence either positively or

negatively the activity of the biologically active heterotetrameric form of the PAH⁷.

Most common PAH mutation causing PKU is IVS 10-11g→a in the Mediterranean region, particularly in Turkey where its frequency is found to be more than 30% of PKU alleles¹¹ and also in a study made on patients of Turkish descent living in Germany, a similar frequency of 38% is obtained¹². IVS 10-11g→a is also found to be the most common PKU mutation in several countries such as; Southern Italy (12.1%)¹³, Sicily (15%)¹⁴, Spain (13.8%)¹⁵ and Portugal (14.6%)¹⁶. Our finding of the frequency for IVS10-11g→a mutation may suggest a selection due to the high frequency of different ethnic groups and consanguineous marriages in Çukurova region¹⁷.

IVS10-11g→a is probably an ancient mutation that originated long before the end of the last ice age and separated into different alleles and subsequently spread with Neolithic farmers through the Mediterranean in early prehistory (in the Middle East by 8.000 BC)^{18,19}. Thus looking at the earlier frequency (1/34) records for the heterozygous form of PAH gene in Turkey¹¹, the frequency of this ancient gene mutation seems to continue increasingly since our findings are considerably higher than the previous records.

Our finding of R261Q mutation as the secondly most frequent mutation is concordant with the allelic frequency found in Turkey by Turkish researchers and among Turkish immigrants living in Germany as detected by German researchers¹². This important mutation observed in a frequency of 13% in European population is another point of interest. The arginine amino acid, accounting for 68.4% of changes in exon sites 7 and 12 where R243X, R243Q, R261Q and R408W mutations occur, is thought to be important for amino acid changes in PAH gene among PKU patients in Çukurova region. However, this result is concordant with ethnicity/region findings for Turkish population presented at pahdb web site, revealing arginine as the most frequent amino acid change with 31.5% (18/57).

Of mutations including IVS10-11g→a in intron 10 which is particularly important for Turkish population, almost 87% occur in between exons 7 to 11. This high frequency may in-turn indicate that the active domain of the enzyme may be coded at this region²⁰.

Although the frequency of the R408W mutation in Turkey is lower than that in European populations, the similarity of frequency for R261Q mutation and V254V polymorphisms in Turkish and European populations can be explained by the gene flow in the geographical area.

ARMS technique, generally considered among conventional techniques used for the detection of single base mutations, it seems to be advantageous in comparison to ASO requiring radioactive chemicals, to RFLP requiring pure DNA for a clean cut, and to sequencing techniques that are expensive in countries like Turkey, however it also has some disadvantage, due to the problems arising from the design of primers.

Provided that primers are carefully designed, ARMS technique can be successfully used for the verification of other molecular techniques or applied alone for the molecular diagnosis of diseases like phenylketonuria by the detection of IVS10-11g→a PAH gene mutation with a frequency of 38% to 59% in Turkish population, FMF (Familial Mediterranean Fever) which occurs in the same region and Mediterranean countries by the detection of major mutations in 85% of cases; Thalassemia by detection of IVS1-110g→a mutation in 55 to 60% of the cases and CF (cystic fibrosis) with ΔF508 mutation in 80% of cases.

REFERENCES

1. Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. *Clin Biochem Rev.* 2008;29:31-41.
2. DiLella AG, Kwok SC, Ledley FD, Marvit J, Woo SL. Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. *Biochemistry.* 1986;25:743-9.
3. Brautigam S, Kujat A, Kirst P, Seidel J, Luleyap HU, Froster UG. DHPLC mutation analysis of phenylketonuria. *Mol Genet Metab.* 2003;78:205-10.
4. Krivokuca A, Yanowski K, Rakobradovic J, Benitez J, Brankovic-Magic M. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families. *Cancer Biomark.* 2015;15:775-81.
5. Hadiji-Abbes N, Trifa F, Choura M, Khabir A, Sellami-Boudawara T, Frikha M et al. A novel BRCA2 in frame deletion in a Tunisian woman with early onset sporadic breast cancer. *Pathol Biol (Paris).* 2015;63:185-9.
6. Sorio C, Angiari C, Johansson J, Verze G, Ettorre M, Buffelli M et al. Impaired CFTR function in mild

- cystic fibrosis associated with the S977F/T5TG12 complex allele in trans with F508del mutation. *J Cyst Fibros.* 2013;12:821-5.
7. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res.* 1988;16:1215.
 8. Eisenberg S, Aksentjevich I, Deng Z, Kastner DL, Matzner Y. Diagnosis of familial Mediterranean fever by a molecular genetics method. *Ann Intern Med.* 1998;129:539-42.
 9. Zhu T, Qin S, Ye J, Qiu W, Han L, Zhang Y et al. Mutational spectrum of phenylketonuria in the Chinese Han population: a novel insight into the geographic distribution of the common mutations. *Pediatr Res.* 2010;67:280-5.
 10. Blau N. Genetics of Phenylketonuria: Then and Now. *Hum Mutat.* 2016;37:508-15.
 11. Ozguc M, Ozalp I, Coskun T, Yilmaz E, Erdem H, Ayter S. Mutation analysis in Turkish phenylketonuria patients. *J Med Genet.* 1993;30:129-30.
 12. Zschocke J, Hoffmann GF. Phenylketonuria mutations in Germany. *Hum Genet.* 1999;104:390-8.
 13. Trunzo R, Santacroce R, D'Andrea G, Longo V, De Girolamo G, Dimatteo C et al. Phenylalanine hydroxylase deficiency in south Italy: Genotype-phenotype correlations, identification of a novel mutant PAH allele and prediction of BH4 responsiveness. *Clin Chim Acta.* 2015;450:51-5.
 14. Guldberg P, Romano V, Ceratto N, Bosco P, Ciuna M, Indelicato A et al. Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe. *Hum Mol Genet.* 1993;2:1703-7.
 15. Couce ML, Boveda MD, Fernandez-Marmiesse A, Miras A, Perez B, Desviat LR et al. Molecular epidemiology and BH4-responsiveness in patients with phenylalanine hydroxylase deficiency from Galicia region of Spain. *Gene.* 2013;521:100-4.
 16. Rivera I, Mendes D, Afonso A, Barroso M, Ramos R, Janeiro P et al. Phenylalanine hydroxylase deficiency: molecular epidemiology and predictable BH4-responsiveness in South Portugal PKU patients. *Mol Genet Metab.* 2011;104:86-92.
 17. Ulusoy M, Tuncbilek E. [Consanguineous marriage in Turkey and its effects on infant mortality]. *Nufusbil Derg.* 1987;9:7-26.
 18. Dianzani I, Giannattasio S, de Sanctis L, Marra E, Ponzzone A, Camaschella C et al. Genetic history of phenylketonuria mutations in Italy. *Am J Hum Genet.* 1994;55:851-3.
 19. Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. *Adv Genet.* 1995;32:199-271.
 20. Luleyap HU, Alptekin D, Pazarbasi A, Kasap M, Kasap H, Demirhindi H et al. The importance of arginine mutation for the evolutionary structure and function of phenylalanine hydroxylase gene. *Mutat Res.* 2006;601:39-45.